Clinical trial
An Open-label, Multi-cohort, Multi-center Phase I Study Evaluating the Efficacy and Safety of MGD013 in Patients With Unresectable, Recurrent or Metastatic Malignant Melanoma
NCT04653038 is registered in ClinicalTrials.gov with Zai Lab (Shanghai) Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Multi-cohort, Multi-center Phase I Study Evaluating the Efficacy and Safety of MGD013 in Patients With Unresectable, Recurrent or Metastatic Malignant Melanoma
- Lead sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- October 29, 2020
- Completion date
- March 2, 2022
- Enrollment
- 92 (actual)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.
unresectable, recurrent or metastatic melanoma, untreated mucosal or acral lentiginous melanoma